KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Bijal Shah(Boston College), William G. Wierda(University of Maryland, Baltimore), Januario E. Castro(La Jolla Alcohol Research), Martha Arellano(Memorial Sloan Kettering Cancer Center), Remus Vezan(National University of Misiones), Mehrdad Abedi(UC Davis Comprehensive Cancer Center), William B. Donnellan(Sarah Cannon), Gary J. Schiller(Fred Hutch Cancer Center), John M. Pagel(University of Washington), Tong Shen(Qingdao University of Science and Technology), Olalekan O. Oluwole(Vanderbilt University), Maria R. Baer(University of Maryland, Baltimore), Adriana K. Malone(Icahn School of Medicine at Mount Sinai), Adrian Bot(Unknown), Lovely Goyal(Gilead Sciences (Australia)), Aaron C. Logan(University of California, San Francisco), Ryan D. Cassaday(University of Washington), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Armin Ghobadi(Washington University in St. Louis), Michael R. Bishop(University of Chicago), Yi Lin, Raya Mawad(Fred Hutch Cancer Center), Jae H. Park(Memorial Sloan Kettering Cancer Center), Houston Holmes(Texas Oncology), Rajul K. Jain(Amgen (United States)), John M. Rossi(Amgen (United States)), Kristen M. O’Dwyer(University of Rochester Medical Center)
Cited by 204
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k